>Anyway, it's all a moot point if the IONIC trial is not going...

>Anyway, it's all a moot point if the IONIC trial is not going to proceed anyway, which is hinted at by de Souza moving on to spending his time with Filamon.<

zecs, I like reading your posts, but this is bullshit.

Paul de Souza is Principal Investigator of a number of clinical trials, including IONIC. During his career he has been able to combine these roles with other trivial things such as employment as the Dean of Medicine at Wollongong University. He has simultaneously studied the mechanism of action of one of Filamon's assets for many years, including in a clinical trial.

Graham Kelly owed Paul a debt for saving his life, and agreed to use his experience to list Filamon on the ASX. GK is still Noxopharm's largest shareholder and only took on the Filamon role once he was satisfied that Filamon would not be in competition with NOX.

IONIC is a major opportunity for NOX, provided Mautner and Bart don't stuff it up the IP. It is inconceivable that de Souza would drop IONIC before he has had the chance to publish results at ASCO.